Step 6: Monitor and adjust Review progress at 4-week intervals
Its unlikely to become available to patients until 2027 at the soonest
1,2 It is coabsorbed with intrinsic factor, a product of the stomach's parietal cells, in the terminal ileum after being extracted by gastric acid 1,2 (Figure 1 3 )
CagriSema is not yet FDA-approved in the United States
To maximise the cardiovascular benefits of GLP-1 RAs at a population level, strategies can be used to improve tolerability, such as patient counselling, gradual dose escalation and the use of long-acting formulations [27]
Tran S-L, Puhar A, Ngo-Camus M, Ramarao N